Antiretroviral agents and acid-base balance at delivery of the neonate

P. El-Beitune1,3, G. Duarte1, E.N. de Morais2, O. Campbell2, P. Spara-Gadelha1, F. Mauad-Filho1, S.M. Quintana1, and L.C. Rodrigues3

Abstract

Limited evidence is available regarding antiretroviral (ARV) safety for uninfected infants exposed to these drugs in utero. Our objective was to determine if ARV administered to pregnant women is associated with decreasing umbilical arterial pH and base excess in uninfected infants. A prospective study was conducted on 57 neonates divided into three groups: ZDV group, born to mothers taking zidovudine (N = 20), triple therapy (TT) group, born to mothers taking zidovudine + lamivudine + nelfinavir (N = 25), and control group (N = 12), born to uninfected mothers. Umbilical cord blood was used to determine umbilical artery gases. A test was performed to calculate the sample by comparing means by the unpaired one-tailed t-test, with α = 0.05 and β = 20%, indicating the need for a sample of 18 newborn infants for the study groups to detect differences higher than 20%. The control and ARV groups were similar in gestational age, birth weight, and Apgar scores. Values of pH, pCO2, bicarbonate, and base excess in cord arterial blood obtained at delivery from the newborns exposed to TT were 7.23, 43.2 mmHg, 19.5 mEq/L, and -8.5 nmol/L, respectively, with no significant difference compared to the control and ZDV groups. We conclude that intrauterine exposure to ARV is not associated with a pathological decrease in umbilical arterial pH or base excess. While our data are reassuring, follow-up is still limited and needs to be continued into adulthood because of the possible potential for adverse effects of triple antiretroviral agents.

Pregnant women are increasingly being treated with multiple antiretroviral (ARV) drugs to improve maternal health and to reduce the risk of vertical transmission of HIV infection. Nucleoside reverse transcriptase inhibitors cross the placenta and reach a variable newborn/mother drug ratio, i.e., approximately 0.85 for zidovudine (ZDV) and 1.0 for lamivudine. Although this maternal-fetal transfer is beneficial for the prevention of the vertical transmission of HIV-1, it may expose the infant to the risk of adverse effects (1,2).

Although this subject is controversial,
prophylaxis with ZDV has been implicated in changes in the neurological and cognitive development of children exposed to HIV but not infected with the virus (3). Limited evidence is available regarding ARV safety for uninfected infants exposed to these drugs in utero. Most of the studies that have addressed the intrauterine well-being of these infants have determined a perinatal prognosis based on Apgar scores and fetal and neonatal death (4,5). In addition, umbilical artery blood pH and gas analysis are increasingly recognized as the most reliable indicators of fetal oxygenation and acid-base condition at birth (6,7). Therefore, our objective was to evaluate the effect of two different intrauterine exposures, ZDV alone or triple antiretroviral treatment with ZDV, lamivudine (3TC) and nelfinavir (NFV) on the umbilical artery blood pH and gas analysis at birth in HIV-exposed children.

We carried out a prospective study on 45 HIV-1-infected women and 12 uninfected pregnant women with singleton gestations. Only HIV-infected patients who had not been treated previously with ARV were selected for the study. The HIV-1-infected women were divided into two groups named ZDV group and triple treatment (TT) group. The ZDV group consisted of 20 pregnant women who fulfilled the requirements for the prophylactic use of ZDV (CD4 >500 cells/mm3 and viral load <1000 copies/mL). The TT group consisted of 25 pregnant women who fulfilled the requirements for the prophylactic use of ZDV (CD4 >500 cells/mm3 and viral load <1000 copies/mL). The ARV agents recommended since the 14th week of pregnancy were ZDV, 300 mg/dose, twice a day for the ZDV group, and 300 mg ZDV, 150 mg 3TC, and 1250 mg NFV in two daily doses for the TT group. The present study was approved by the Research Ethics Committee of the Institution, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil, and written informed consent to participate was obtained from each subject.

To evaluate factors potentially associated with umbilical arterial blood pH abnormalities from birth, we adjusted analyses for gestational age at birth, mode of delivery, alcohol use, illicit drug use during gestation, and tobacco use. Pregnant women with hypertension, diabetes mellitus, seizures, stillbirth, or macrosomia in their previous pregnancies, and pathological fetal heart rate tracings and women who did not comply with the use of ARV drugs or used them irregularly and also infants presenting congenital infections or malformations were excluded. Biochemical evaluation was not concluded in two ZDV group and three TT group infants due to concomitance of exclusion criteria.

Blood samples were drawn from a doubly clamped cord segment into 3-mL plastic syringes flushed with a 1000-U/mL heparin solution. Measurements were performed within 15 min after delivery. Arterial blood gases were determined by an automated method using the Rapid Lab-860 system of Bayer (Tarrytown, NY, USA). Since we expected that the use of ARV drugs during pregnancy would elevate pCO2 and reduce pH and base excess compared to controls (12 newborn infants), a test was performed to calculate the sample by comparing means by the unpaired one-tailed t-test, with $\alpha = 0.05$ and $\beta = 20\%$, indicating the need for a sample of 18 newborn infants for the study groups, considering the interest in detecting pathologic data of pCO2 of about 65 mmHg, pH 7.10, and base excess higher than 12 nmol/L. The GraphPad StatMate 1.01 software was used for these calculations.

The variability of the acid-base balance in cord arterial blood was calculated on the
basis of the median and interquartile variation (1st and 3rd quartiles, respectively). The nonparametric chi-square, Mann-Whitney and Kruskal-Wallis tests were used, with the level of significance set at P < 0.05. All analyses were performed using the SPSS 10.0 software.

Median maternal age was 22.5 years, with an interquartile (IQ) variation of 6 years in the control group, 24 years (IQ of 7 years) in the ZDV group, and 27 years (IQ of 6 years) in the TT group, with no significant difference in these variables between groups (Kruskal-Wallis test, P = 0.13). With respect to race (white and non-white), 83, 50, and 68% of the women in the control, ZDV and TT groups were white, respectively (chi-square test, P = 0.14). Smoking habits also were not significantly different, with 91, 60, and 80% of the subjects in the control, ZDV and TT groups being non-smokers, respectively (chi-square test, P = 0.14). Alcohol drinking also did not differ significantly between groups (chi-square test, P = 0.14).

Median gestational age at delivery was 39 weeks for the control group, 38.1 weeks for the ZDV group and 38.5 weeks for the TT group (Kruskal-Wallis test, P = 0.57). Median infant weight was 3250, 3080, and 3100 g for the control, ZDV and TT groups, respectively (Kruskal-Wallis test, P = 0.447). Analysis of these variables, of the Apgar score and of adequacy of anthropometric classification did not indicate any significant differences among the newborns of the various groups (chi-square test, P = 0.59). Cesarean section was performed in 16.7, 45.0, and 36.0% of the control, ZDV and TT groups, respectively (chi-square test, P = 0.26).

Table 1 presents the values of pH, pCO\(_2\), bicarbonate, and base excess in cord arterial blood from the newborn at the time of delivery. No significant differences were observed between cases and controls. Even though the results of the present series support the safety of the use of two schemes of ARV therapy during pregnancy, i.e., ZDV prophylaxis and combination of ARV agents, a limitation exists, based on the power of the study reported here to detect an effect of lower magnitude among groups.

In the present patient series, no difference in gestational age or in newborn birth weight was observed, nor did the 1st and 5th min Apgar scores differ between the three groups studied. These data are similar to those obtained in other studies and meta-analyses which demonstrated that the gestational and immediate neonatal prognosis were not impaired among pregnant women exclusively taking ZDV or taking drug combinations containing or not protease inhibitors during the prenatal period (8-11).

Despite the vast literature available about the potentiation of the adverse effects of ARV in adults (2,11,12), there are no prospective studies emphasizing the effect of

<table>
<thead>
<tr>
<th>Group</th>
<th>pH</th>
<th>pCO(_2) (mmHg)</th>
<th>HCO(_3) (mEq/L)</th>
<th>BE (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (N = 12)</td>
<td>7.25 (7.20-7.28)</td>
<td>40.0 (31.9-48.9)</td>
<td>17.7 (15.1-18.9)</td>
<td>-10.3 (-10.9 to -6.9)</td>
</tr>
<tr>
<td>ZDV (N = 18)</td>
<td>7.22 (7.14-7.26)</td>
<td>47.3 (41.9-51.9)</td>
<td>18.3 (16.9-20.3)</td>
<td>-8.8 (-11.6 to -6.9)</td>
</tr>
<tr>
<td>TT (N = 22)</td>
<td>7.23 (7.15-7.30)</td>
<td>43.2 (40.6-46.6)</td>
<td>19.5 (17.3-20.7)</td>
<td>-8.5 (-12.6 to -5.8)</td>
</tr>
<tr>
<td>P</td>
<td>0.24</td>
<td>0.11</td>
<td>0.13</td>
<td>0.72</td>
</tr>
</tbody>
</table>

Data are reported as medians and 1st and 3rd quartiles. Control = uninfected pregnant women with no antiretroviral agents; ZDV = 300 mg zidovudine twice a day; TT = triple therapy with 300 mg zidovudine + 150 mg lamivudine + 1250 mg nelfinavir twice a day. There were no statistically significant differences between groups (Kruskal-Wallis test).
maternal ARV agent use on acid-base balance at delivery of the neonate, which objectively reflects the placental respiratory and metabolic conditions of the infant at birth, using these data as a basis for the clinical results observed (7,13,14).

The pH value observed was 7.25 for the control group, with no significant differences compared to the cases. Similarly, placental respiratory and metabolic function did not differ between groups. Our clinical data agree with those reported for children exposed to HIV but not infected followed up in the multicenter PACTG 076 study for a mean period of 4.2 years (range: 3.2-5.6 years), in which no difference in neurological, cognitive or behavioral development was observed compared to the control group (15). In addition, in a meta-analysis conducted on a total of 2123 HIV-infected pregnant women who had received ARV therapy during the prenatal period (ZDV alone in 1590, combined therapy without protease inhibitors in 396, and combined therapy with protease inhibitors in 137) and on 1143 women who did not receive ARV therapy during pregnancy, the use of ARV medications was also not associated with low Apgar scores or fetal death compared to untreated women or women taking ZDV alone (9).

In conclusion, no association was observed between the use of ARV drugs and pathological gas changes in umbilical cord arterial blood, with similar data being detected for the three groups regarding pH, pCO$_2$, base deficit, and bicarbonate. Our results suggest safety of the use of ARV drugs during pregnancy regarding fetal oxygenation and acid-base condition at birth. On the other hand, the “gold standard” is to conduct follow-up of children with intrauterine ARV drug exposure into adulthood because of the possible potential for adverse metabolic and hematological effects of a combined scheme with protease inhibitors (16,17).

References


